Marshall Wace North America L.P. boosted its position in shares of Novartis AG (NYSE:NVS) by 39.0% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 964,946 shares of the company’s stock after buying an additional 270,799 shares during the period. Novartis AG makes up approximately 0.6% of Marshall Wace North America L.P.’s holdings, making the stock its 29th largest position. Marshall Wace North America L.P.’s holdings in Novartis AG were worth $80,091,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of NVS. Primecap Management Co. CA increased its position in Novartis AG by 2.1% in the first quarter. Primecap Management Co. CA now owns 21,693,804 shares of the company’s stock worth $1,611,199,000 after buying an additional 446,976 shares in the last quarter. Wells Fargo & Company MN increased its position in Novartis AG by 12.2% in the first quarter. Wells Fargo & Company MN now owns 9,100,801 shares of the company’s stock worth $675,917,000 after buying an additional 988,301 shares in the last quarter. Parnassus Investments CA increased its position in Novartis AG by 89.4% in the first quarter. Parnassus Investments CA now owns 8,173,974 shares of the company’s stock worth $593,720,000 after buying an additional 3,858,632 shares in the last quarter. Bank of America Corp DE increased its position in Novartis AG by 7.5% in the first quarter. Bank of America Corp DE now owns 7,328,730 shares of the company’s stock worth $544,304,000 after buying an additional 508,435 shares in the last quarter. Finally, Fisher Asset Management LLC increased its position in Novartis AG by 6.3% in the second quarter. Fisher Asset Management LLC now owns 6,505,935 shares of the company’s stock worth $543,050,000 after buying an additional 384,262 shares in the last quarter. Hedge funds and other institutional investors own 10.97% of the company’s stock.

Novartis AG (NYSE:NVS) opened at 83.62 on Wednesday. The stock’s 50 day moving average price is $83.94 and its 200 day moving average price is $79.45. Novartis AG has a 52 week low of $66.93 and a 52 week high of $86.90. The stock has a market cap of $195.91 billion, a price-to-earnings ratio of 30.53 and a beta of 0.73.

Novartis AG (NYSE:NVS) last issued its earnings results on Tuesday, July 18th. The company reported $1.22 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.16 by $0.06. Novartis AG had a return on equity of 15.51% and a net margin of 13.52%. The firm had revenue of $12.24 billion for the quarter, compared to analysts’ expectations of $12.20 billion. During the same quarter last year, the firm earned $1.23 earnings per share. The firm’s revenue for the quarter was down 1.8% compared to the same quarter last year. On average, analysts forecast that Novartis AG will post $4.74 earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: This news story was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this news story on another domain, it was stolen and reposted in violation of United States & international trademark and copyright law. The original version of this news story can be viewed at https://www.thecerbatgem.com/2017/08/30/marshall-wace-north-america-l-p-boosts-position-in-novartis-ag-nvs.html.

A number of research analysts have recently commented on NVS shares. J P Morgan Chase & Co reiterated a “neutral” rating on shares of Novartis AG in a research report on Thursday, June 22nd. BidaskClub upgraded Novartis AG from a “sell” rating to a “hold” rating in a research report on Saturday, August 5th. Cowen and Company restated a “hold” rating on shares of Novartis AG in a research report on Tuesday, July 18th. UBS AG restated a “neutral” rating on shares of Novartis AG in a research report on Tuesday, May 30th. Finally, Zacks Investment Research downgraded Novartis AG from a “hold” rating to a “sell” rating in a research report on Monday, July 10th. Three analysts have rated the stock with a sell rating, ten have issued a hold rating and six have issued a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus price target of $83.56.

In other news, major shareholder Bioventures Ltd Novartis bought 266,667 shares of Novartis AG stock in a transaction that occurred on Wednesday, July 5th. The shares were purchased at an average price of $15.00 per share, for a total transaction of $4,000,005.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 0.01% of the stock is currently owned by company insiders.

Novartis AG Company Profile

Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company’s segments include Innovative Medicines, Sandoz, Alcon and Corporate activities.

Want to see what other hedge funds are holding NVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novartis AG (NYSE:NVS).

Institutional Ownership by Quarter for Novartis AG (NYSE:NVS)

Receive News & Stock Ratings for Novartis AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis AG and related stocks with our FREE daily email newsletter.